The Magazine for Sleep Professionals
Wednesday, May 6, 2026
Dental Sleep Medicine | Sleep Disorders | Testing Modalities & Diagnostics | Patient Health | Pharmaceuticals | Research/Studies
Many more people work very early morning shifts than overnight ones, and a large proportion struggle with excessive sleepiness from shift work disorder, leading to problems with focus, performance and safety. A new clinical trial by investigators from Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early […]
Apnimed, Inc., announced that it has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners (“HCRx”). The capital is expected to support commercial readiness activities and the planned U.S. launch of Apnimed’s lead product candidate, AD109, if approved by the […]
As a sleep physician, one of the most frustrating realities I encounter is not a lack of diagnostic tools, but the barriers patients face in accessing them. Obstructive sleep apnea (OSA) is common, serious, and widely underdiagnosed. Estimates suggest that more than 30 million adults in the United States are […]
Alkermes plc, announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development […]
Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, […]
Eli Lilly and Company and Centessa Pharmaceuticals plc, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Lilly to acquire Centessa. Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to […]
Narcolepsy is a chronic condition in which someone feels excessively sleepy, occasionally falling asleep without warning. This can have a major impact on their daily lives, affecting not only their education and employment, but also their ability to drive, their relationships, and their emotional health. “It’s quite striking when you’re […]
AI software designed to help diagnose sleep apnea in children has achieved high accuracy in an NHS trial, with the findings independently reviewed by clinical specialists. Glasgow company Seluna tested its autoscoring and sleep staging software on 500 retrospective sleep studies from NHS Greater Glasgow and Clyde’s Royal Hospital for […]
LivaNova PLC announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with […]
Wesper announces Robert Wood Johnson University Hospital (RWJUH) Somerset has expanded monthly sleep testing capacity by 290% following the adoption of Wesper’s direct-to-patient, dropship home sleep testing model, according to a newly released whitepaper detailing the operational transformation. Prior to implementation, RWJUH Somerset faced growing demand for sleep apnea testing […]
